NCCTG N0879 (Alliance): A randomized phase 2 cooperative group trial of carboplatin, paclitaxel, and bevacizumab ± everolimus for metastatic melanoma.
Robert R McWilliamsJacob B AllredJessica A SlostadRajini KatipamulaRoxana S DroncaKandelaria M RumillaLori A EricksonAlan H BryceRichard W JosephLisa A KottschadeDavid M KingJohn M LeitchSvetomir N MarkovicPublished in: Cancer (2017)
Both experimental arms demonstrated activity, with a PFS of >5 months. However, the addition of everolimus to CPB failed to improve outcomes, with increased toxicity noted. These findings replicate the moderate antitumor activity of CPB, with future development possibly in combination with targeted or immunotherapy. Cancer 2018;124:537-45. © 2017 American Cancer Society.